Helena Fohlin

1.3k total citations · 1 hit paper
23 papers, 957 citations indexed

About

Helena Fohlin is a scholar working on Oncology, Cancer Research and Genetics. According to data from OpenAlex, Helena Fohlin has authored 23 papers receiving a total of 957 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 10 papers in Cancer Research and 8 papers in Genetics. Recurrent topics in Helena Fohlin's work include Breast Cancer Treatment Studies (8 papers), Estrogen and related hormone effects (7 papers) and Cancer Risks and Factors (4 papers). Helena Fohlin is often cited by papers focused on Breast Cancer Treatment Studies (8 papers), Estrogen and related hormone effects (7 papers) and Cancer Risks and Factors (4 papers). Helena Fohlin collaborates with scholars based in Sweden, United States and Germany. Helena Fohlin's co-authors include Johan Rosell, Sherry Yueh‐Hsia Chiu, Amy Ming‐Fang Yen, Chien‐Jen Chen, Tibor Tot, Bedrich Viták, Làszló Tabár, Stephen W. Duffy, Jean Ching‐Yuan Fann and Anders Cohen and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Radiology.

In The Last Decade

Helena Fohlin

22 papers receiving 917 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Swedish Two-County Trial: Impact of Mammographic Screening on Breast Cancer Mortality during 3 Decades

2011 549 citations Làszló Tabár, Bedrich Viták et al. Radiology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Helena Fohlin Sweden	12	552	302	283	199	187	23	957
Olorunsola F. Agbaje United Kingdom	15	438 0.8×	262 0.9×	171 0.6×	201 1.0×	176 0.9×	26	971
Chris I. Flowers United States	12	412 0.7×	349 1.2×	322 1.1×	218 1.1×	247 1.3×	23	1.1k
Isabel Amendoeira Portugal	15	617 1.1×	449 1.5×	369 1.3×	179 0.9×	224 1.2×	45	1.5k
Jafi A. Lipson United States	19	336 0.6×	388 1.3×	290 1.0×	253 1.3×	357 1.9×	43	974
Sally D. Herschorn United States	17	482 0.9×	220 0.7×	343 1.2×	379 1.9×	335 1.8×	44	1.0k
Laura Esserman United States	11	511 0.9×	249 0.8×	137 0.5×	80 0.4×	267 1.4×	31	909
Melissa Zhao United States	8	257 0.5×	372 1.2×	198 0.7×	115 0.6×	125 0.7×	15	909
Marissa C. van Maaren Netherlands	15	527 1.0×	738 2.4×	152 0.5×	133 0.7×	155 0.8×	53	1.2k
Ninah Achacoso United States	19	456 0.8×	331 1.1×	158 0.6×	93 0.5×	95 0.5×	49	808
Ku Sang Kim South Korea	18	210 0.4×	247 0.8×	156 0.6×	106 0.5×	249 1.3×	43	858

Countries citing papers authored by Helena Fohlin

Since Specialization

Citations

This map shows the geographic impact of Helena Fohlin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Helena Fohlin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Helena Fohlin more than expected).

Fields of papers citing papers by Helena Fohlin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Helena Fohlin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Helena Fohlin. The network helps show where Helena Fohlin may publish in the future.

Co-authorship network of co-authors of Helena Fohlin

This figure shows the co-authorship network connecting the top 25 collaborators of Helena Fohlin. A scholar is included among the top collaborators of Helena Fohlin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Helena Fohlin. Helena Fohlin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fohlin, Helena, Anna Nordenskjöld, Johan Rosell, et al.. (2024). Breast cancer hormone receptor levels and benefit from adjuvant tamoxifen in a randomized trial with long-term follow-up. Acta Oncologica. 63. 535–541. 4 indexed citations

Nordenskjöld, Anna, Helena Fohlin, Johan Rosell, et al.. (2023). Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy. The Breast. 71. 63–68. 2 indexed citations

Schmitt‐Egenolf, Marcus, et al.. (2023). Patient reported experiences of Swedish patients being investigated for cancer during the Covid-19 pandemic. Supportive Care in Cancer. 31(7). 416–416.

Fohlin, Helena, Gunilla Enblad, Bengt Glimelius, et al.. (2022). Limited, But Not Eliminated, Excess Long-Term Morbidity in Stage I-IIA Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine and Limited-Field Radiotherapy. Journal of Clinical Oncology. 40(13). 1487–1496. 12 indexed citations

Fohlin, Helena, Per Albertsson, L-G Arnesson, et al.. (2021). Survival patterns of invasive lobular and invasive ductal breast cancer in a large population-based cohort with two decades of follow up. The Breast. 59. 294–300. 22 indexed citations

Holte, Harald, Ingrid Glimelius, Magnus Björkholm, et al.. (2019). No excess long‐term mortality in stage I‐IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapy. British Journal of Haematology. 188(5). 685–691. 18 indexed citations

Nordenskjöld, Anna, Helena Fohlin, Zakaria Einbeigi, et al.. (2018). Breast cancer survival trends in different stages and age groups – a population-based study 1989–2013. Acta Oncologica. 58(1). 45–51. 24 indexed citations

Nordenskjöld, Anna, et al.. (2016). Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer. Breast Cancer Research and Treatment. 160(2). 313–322. 32 indexed citations

Johansson, Henrik J., Jenny Forshed, Olle Stål, et al.. (2015). Proteomics profiling identify CAPS as a potential predictive marker of tamoxifen resistance in estrogen receptor positive breast cancer. Clinical Proteomics. 12(1). 8–8. 31 indexed citations

10.

Nordenskjöld, Anna, Helena Fohlin, Per Albertsson, et al.. (2015). No clear effect of postoperative radiotherapy on survival of breast cancer patients with one to three positive nodes: a population-based study. Annals of Oncology. 26(6). 1149–1154. 26 indexed citations

11.

Fohlin, Helena, et al.. (2014). A randomised approximation algorithm for the hitting set problem. Theoretical Computer Science. 555. 23–34. 5 indexed citations

12.

Fohlin, Helena, Gizeh Pérez‐Tenorio, Tommy� Fornander, et al.. (2013). Akt2 expression is associated with good long-term prognosis in oestrogen receptor positive breast cancer. European Journal of Cancer. 49(6). 1196–1204. 9 indexed citations

13.

Sörenson, Sverre, Helena Fohlin, Andrea Lindgren, et al.. (2012). Predictive role of plasma vascular endothelial growth factor for the effect of celecoxib in advanced non-small cell lung cancer treated with chemotherapy. European Journal of Cancer. 49(1). 115–120. 13 indexed citations

14.

Tabár, Làszló, Bedrich Viták, Chien‐Jen Chen, et al.. (2011). Swedish Two-County Trial: Impact of Mammographic Screening on Breast Cancer Mortality during 3 Decades. Radiology. 260(3). 658–663. 549 indexed citations breakdown →

15.

Sundqvist, Martina, Helena Fohlin, F. Spyratos, et al.. (2010). Prolonged tamoxifen treatment increases relapse-free survival for patients with primary breast cancer expressing high levels of VEGF. European Journal of Cancer. 46(9). 1580–1587. 8 indexed citations

16.

Koch, Andrea, Bertil Gustafsson, Helena Fohlin, & Sverre Sörenson. (2010). Cyclooxygenase‐2 expression in lung cancer cells evaluated by immunocytochemistry. Diagnostic Cytopathology. 39(3). 188–193. 6 indexed citations

17.

Fohlin, Helena, Tommy� Fornander, Olle Stål, et al.. (2010). Immunohistochemistry compared to cytosol assays for determination of estrogen receptor and prediction of the long-term effect of adjuvant tamoxifen. Breast Cancer Research and Treatment. 126(2). 421–430. 48 indexed citations

18.

Koch, Andrea, Helena Fohlin, & Sverre Sörenson. (2009). Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy. Journal of Thoracic Oncology. 4(3). 326–332. 85 indexed citations

19.

Hackshaw, A., Michael Baum, Tommy� Fornander, et al.. (2009). Long-term Effectiveness of Adjuvant Goserelin in Premenopausal Women With Early Breast Cancer. JNCI Journal of the National Cancer Institute. 101(5). 341–349. 41 indexed citations

20.

Siebert, Frank‐André, et al.. (2007). Three‐dimensional reconstruction of seed implants by randomized rounding and visual evaluation. Medical Physics. 34(3). 967–975. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact